CAST's Clinical Trial Manuscript Published
Core Access Surgical Technologies, Inc. (CAST) is thrilled to announce that their latest Clinical Trial Manuscript has gained acceptance for publication in a leading journal devoted to minimally invasive surgical practices. This achievement highlights the importance of the LevaLap™ 1.0 device, which has been making significant strides in surgical settings worldwide. This publication not only confirms the device's clinical effectiveness but also its growing value among contemporary surgeons and key opinion leaders.
Significance of the LevaLap™ 1.0 Device
Innovative Benefits for Surgeons
The study asserts that even seasoned surgeons can greatly benefit from using the LevaLap™ 1.0 during laparoscopic procedures. The device enhances ease of use, control, and safety when accessing the abdomen using the Veress needle. These findings suggest a pivotal shift in laparoscopic methods, emphasizing LevaLap's potential to improve surgical efficiency across the board.
Gratitude for Scientific Contribution
The firm expressed deep gratitude to the Journal of the Society of Laparoscopic Surgeons for their support in disseminating vital research. The JSLS serves as a pivotal resource in promoting minimally invasive surgery by encouraging scientific exchange and clinical innovation. CAST is proud to contribute to the progress in the surgery field.
A Global Confirmation of Surgical Excellence
Enhancing Surgical Outcomes Worldwide
CAST takes pride in celebrating the significant milestone that validates the global harmonization of the Veress Needle access technique. The multicenter, multi-country study demonstrates the device's versatility, efficacy, and safety among various surgeons with different access techniques. This achievement underlines the successful application of the LevaLap™ 1.0 method in enhancing surgical outcomes in laparoscopic procedures.
Leadership Insights
"We are excited about the advancements represented by this study and its positive implications for surgical practices globally," said Thomas A. Gordy, Chairman and CEO of CAST. The outcomes underscore the progress in standardizing the laparoscopic access approach, continuing CAST's commitment to revolutionizing laparoscopic surgery.
About Core Access Surgical Technologies, Inc.
CAST is a premier global medical device company focused on developing and distributing advanced laparoscopic surgical tools. Their commitment to precision and risk mitigation in surgical access ensures that they provide innovative and economically viable solutions to the medical community.
About the Journal of the Society of Laparoscopic Surgeons
The Journal of the Society of Laparoscopic & Robotic Surgeons (JSLS) is revered in the field of minimally invasive surgery. Its impressive ranking among thousands of scientific journals signifies its wide readership and engagement with cutting-edge surgical research.
Frequently Asked Questions
What is the significance of the manuscript acceptance by JSLS?
This acceptance signifies that CAST's research on LevaLap™ 1.0 is recognized by a leading journal, highlighting its contributions to minimally invasive surgery.
What does the LevaLap™ 1.0 device do?
The LevaLap™ 1.0 facilitates easier and safer access to the abdomen during laparoscopic surgery, enhancing overall surgical performance.
Who authored the study published in JSLS?
The study was authored by notable surgeon Ricardo Azziz, MD, MPH, among others, contributing to the field through their findings.
How does the study impact future surgical practices?
The study's findings encourage adoption of the LevaLap™ 1.0 device, potentially altering laparoscopic surgery standards worldwide.
Where can I learn more about CAST and its offerings?
Detailed information about CAST and its innovative products can be found on their official website.
